CLINICAL TRIALS PROFILE FOR SPIRIVA RESPIMAT
✉ Email this page to a colleague
All Clinical Trials for SPIRIVA RESPIMAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00239447 ↗ | Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD | Completed | Boehringer Ingelheim | Phase 3 | 2002-11-01 | Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler |
| NCT00281567 ↗ | Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 3 | 2002-08-01 | Comparison of lung function response between tiotropium inhalation solution and Spiriva HandiHaler. |
| NCT00292448 ↗ | A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Completed | Boehringer Ingelheim | Phase 2 | 2006-02-01 | The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in patients with COPD. |
| NCT00981851 ↗ | Interaction in Chronic Obstructive Pulmonary Disease Experiment | Completed | Radboud University | N/A | 2009-09-01 | The final purpose of this study is to determine whether bronchodilation and cigarette smoking in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase of cardiovascular disease. The aim of this part of the study is to demonstrate the basic mechanism: Does increased respiratory function after administration of a bronchodilator in patients with COPD lead to elevated pulmonary retention of the harmful compounds in inhaled cigarette smoke and to short-term biological effects associated with cardiovascular disease? |
| NCT01179347 ↗ | Tiotropium Bromide in Cystic Fibrosis | Completed | Boehringer Ingelheim | Phase 3 | 2010-09-01 | To date, there have been no formal clinical studies completed using tiotropium in CF patients. While there is a large body of evidence demonstrating the efficacy and safety of tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD), relatively little is known about its efficacy and safety in patients with a diagnosis of cystic fibrosis. Therefore, Boehringer Ingelheim proposed to profile the long acting anticholinergic tiotropium and to generate adequate clinical data for use as a bronchodilator in paediatric and adult CF. The phase III trial (205.438) is a part of the approved Paediatric Investigation Plan (PIP) agreed for Spiriva® Respimat® in Cystic Fibrosis. |
| NCT01694771 ↗ | Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® | Completed | Boehringer Ingelheim | Phase 3 | 2012-09-01 | The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPIRIVA RESPIMAT
Condition Name
Clinical Trial Locations for SPIRIVA RESPIMAT
Trials by Country
Clinical Trial Progress for SPIRIVA RESPIMAT
Clinical Trial Phase
Clinical Trial Sponsors for SPIRIVA RESPIMAT
Sponsor Name
